Jarrod Longcor has joined Avillion, a co-developer of late-stage pharmaceutical assets, as Chief Business Officer.
Longcor is responsible for structuring, negotiating and executing partnerships, co-development agreements and financial investments, as well as providing management and strategic leadership to the organisation. He is a member of the Executive leadership team.
Longcor brings to Avillion more than 18 years of pharmaceutical and biotech experience and was previously Vice President of Corporate Development at Rib-X Pharmaceuticals (now Melinta Therapeutics).
Prior to this, he held key positions in several small- to mid-sized biotech companies where he was responsible for business development and strategic planning.
Allison Jeynes-Ellis, Chief Executive of Avillion, said: 'Our first collaborative development programme with Pfizer to conduct a global Phase III trial of Bosulif in chronic myelogenous leukaemia is underway, and Jarrod coming on board enables us to intensify our efforts to complete additional co-development agreements in the coming months.'
